Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Scott T Tagawa

Showing results (141-150 of 208) with videos related to

Pageof 21
Sort By:
European Urology Oncology|July 6, 2024
Intensifying Salvage Therapy in Prostate-specific Antigen Recurrent Prostate Cancer After Radical Prostatectomy with Apalutamide, Salvage Radiation, and Docetaxel: The Phase 2 STARTAR TrialTian Zhang, Lauren Howard, Bridget F Koontz, et al.
Cancer|December 17, 2013
An open-label, single-arm, phase 2 trial of the Polo-like kinase inhibitor volasertib (BI 6727) in patients with locally advanced or metastatic urothelial cancerWalter M Stadler, David J Vaughn, Guru Sonpavde, et al.
Annals of Neurology|May 24, 2021
Mechanisms of Ischemic Stroke in Patients with Cancer: A Prospective StudyBabak B Navi, Carla P Sherman, Richard Genova, et al.
JCO Precision Oncology|May 29, 2020
<i>CDK12</i>-Altered Prostate Cancer: Clinical Features and Therapeutic Outcomes to Standard Systemic Therapies, Poly (ADP-Ribose) Polymerase Inhibitors, and PD-1 InhibitorsEmmanuel S Antonarakis, Pedro Isaacsson Velho, Wei Fu, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 26, 2026
Alliance A222001: Oxybutynin Versus Placebo for the Treatment of Hot Flashes in Patients Receiving Androgen-Deprivation Therapy for Prostate CancerBradley J Stish, Gina L Mazza, Jones T Nauseef, et al.
The New England Journal of Medicine|July 25, 2019
Erdafitinib in Locally Advanced or Metastatic Urothelial CarcinomaYohann Loriot, Andrea Necchi, Se Hoon Park, et al.
The Lancet. Oncology|January 14, 2022
Efficacy and safety of erdafitinib in patients with locally advanced or metastatic urothelial carcinoma: long-term follow-up of a phase 2 studyArlene O Siefker-Radtke, Andrea Necchi, Se Hoon Park, et al.
The Lancet. Oncology|June 3, 2023
Health-related quality of life and pain outcomes with [<sup>177</sup>Lu]Lu-PSMA-617 plus standard of care versus standard of care in patients with metastatic castration-resistant prostate cancer (VISION): a multicentre, open-label, randomised, phase 3 trialKarim Fizazi, Ken Herrmann, Bernd J Krause, et al.
NPJ Precision Oncology|August 6, 2021
A phase I/II study of rovalpituzumab tesirine in delta-like 3-expressing advanced solid tumorsAaron S Mansfield, David S Hong, Christine L Hann, et al.
JCO Precision Oncology|November 6, 2020
Prospective Multicenter Study of Circulating Tumor Cell AR-V7 and Taxane Versus Hormonal Treatment Outcomes in Metastatic Castration-Resistant Prostate CancerAndrew J Armstrong, Jun Luo, David M Nanus, et al.
Pageof 21

Showing results (141-150 of 208) with videos related to

Sort By:
Pageof 21
European Urology Oncology|July 6, 2024
Intensifying Salvage Therapy in Prostate-specific Antigen Recurrent Prostate Cancer After Radical Prostatectomy with Apalutamide, Salvage Radiation, and Docetaxel: The Phase 2 STARTAR TrialTian Zhang, Lauren Howard, Bridget F Koontz, et al.
Cancer|December 17, 2013
An open-label, single-arm, phase 2 trial of the Polo-like kinase inhibitor volasertib (BI 6727) in patients with locally advanced or metastatic urothelial cancerWalter M Stadler, David J Vaughn, Guru Sonpavde, et al.
Annals of Neurology|May 24, 2021
Mechanisms of Ischemic Stroke in Patients with Cancer: A Prospective StudyBabak B Navi, Carla P Sherman, Richard Genova, et al.
JCO Precision Oncology|May 29, 2020
<i>CDK12</i>-Altered Prostate Cancer: Clinical Features and Therapeutic Outcomes to Standard Systemic Therapies, Poly (ADP-Ribose) Polymerase Inhibitors, and PD-1 InhibitorsEmmanuel S Antonarakis, Pedro Isaacsson Velho, Wei Fu, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 26, 2026
Alliance A222001: Oxybutynin Versus Placebo for the Treatment of Hot Flashes in Patients Receiving Androgen-Deprivation Therapy for Prostate CancerBradley J Stish, Gina L Mazza, Jones T Nauseef, et al.
The New England Journal of Medicine|July 25, 2019
Erdafitinib in Locally Advanced or Metastatic Urothelial CarcinomaYohann Loriot, Andrea Necchi, Se Hoon Park, et al.
The Lancet. Oncology|January 14, 2022
Efficacy and safety of erdafitinib in patients with locally advanced or metastatic urothelial carcinoma: long-term follow-up of a phase 2 studyArlene O Siefker-Radtke, Andrea Necchi, Se Hoon Park, et al.
The Lancet. Oncology|June 3, 2023
Health-related quality of life and pain outcomes with [<sup>177</sup>Lu]Lu-PSMA-617 plus standard of care versus standard of care in patients with metastatic castration-resistant prostate cancer (VISION): a multicentre, open-label, randomised, phase 3 trialKarim Fizazi, Ken Herrmann, Bernd J Krause, et al.
NPJ Precision Oncology|August 6, 2021
A phase I/II study of rovalpituzumab tesirine in delta-like 3-expressing advanced solid tumorsAaron S Mansfield, David S Hong, Christine L Hann, et al.
JCO Precision Oncology|November 6, 2020
Prospective Multicenter Study of Circulating Tumor Cell AR-V7 and Taxane Versus Hormonal Treatment Outcomes in Metastatic Castration-Resistant Prostate CancerAndrew J Armstrong, Jun Luo, David M Nanus, et al.
Pageof 21